Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$6.33
▼ $0.03 (-0.5%)
Market data updated: 09/25 03:26 AM
Fundamentals updated: 09/25/2026
News analyzed: 09/25/2026
Market Cap
$174.72M
Day Range
$6.18 - $6.47
52-Week Range
$3.53 - $9.62
Beta
—
Next Earnings
02.11.2026
Support
$6.34
Resistance
$9.34
DTIL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+30.9% (1Y)
Strengths: 6/25 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
Operating margin
Operating margin: -152.2% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
43
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
19d ago · $7.47
Evidence: Narrative Gap moved from 41 to 15 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
58
Value
55
Momentum
28
Risk
40
Sentiment
92
Fundamental
30
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Precision BioSciences, Inc. has focused on its clinical advancements in gene editing therapies, particularly its Phase 1/2 FUNCTION-DMD trial for Duchenne muscular dystrophy (DMD), where the company dosed its first patient with PBGENE-DMD in August 2026. The therapy, leveraging its ARCUS® platform, aims to restore near-full-length dystrophin for up to 60% of DMD patients. Additionally, Precision’s licensed ARCUS® nuclease technology to iECURE for programs like OTC deficiency was highlighted, alongside positive preliminary data from iECURE’s low-dose trial showing reduced hyperammonemic crises. Analysts also noted the company’s speculative growth potential and strong momentum in gene editing.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Precision BioSciences, Inc.. News trend score: 92. Reason: 8 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
34
Psychology
94
Fundamentals
30
Technical
28
Valuation
55
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-6%
Market Narrative
49
Fundamental Reality
34
Narrative Gap
+15
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
DTIL’s psychology profile is dominated by confirmation bias, where investors cling to a +15 narrative gap despite deteriorating fundamentals (revenue decline, shrinking margins). The neutral RSI (42) and muted volatility (0.94x ATR) suggest no panic or euphoria, but the disconnect between narrative (49) and reality (34) hints at selective attention. The key question: will investors remain anchored to optimism or pivot when fundamentals worsen? The lack of herding or anchoring signals keeps behavior detached from peers or support levels.
Updated: 09/07/2026, 12:11 AM
What could change this?
👥 What the crowd believes
"Precision BioSciences announced the dosing of the first patient in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy (DMD)."
"iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs."
"HC Wainwright & Co. reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target."
"iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises."
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a clash between defensive, value-driven methodologies and those skeptical of its stability or growth potential. At the top, Bagehot’s liquidity focus and Graham’s defensive investor framework both see it as a resilient, undervalued opportunity, praising its resilience and statistical discounts. Meanwhile, Nelson’s cyclical analysis leans cautiously optimistic, while Graham’s Enterprising Investor lens still finds it compelling—but only for those comfortable with deeper risk. In contrast, Marks’ mixed verdict and Loeb’s risk warning highlight concerns about overvaluation or hidden vulnerabilities, while Veblen, Smith, and Fisher dismiss it outright for lacking the stability, quality, or growth trajectory they demand. Even Livermore’s trend-following rule and Housel’s patience principle reject it, framing it as either a losing trade or a volatile trap—showing how a single stock can simultaneously appeal to contrarian value hunters and repel momentum-driven or long-term-oriented investors.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 86
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 71
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 56
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 55
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 42
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 30
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 29
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 29
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 26
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 20
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-152.2%
Net Margin
-133.4%
EBITDA Margin
-147.9%
ROE
-49.6%
ROA
-29.6%
ROIC
—
EPS
-$3.56
Cash
$110.82M
Total Debt
—
Current Ratio
13.32
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$7.19
Tangible Book Value per Share (Tangible NAV)
$7.10
Sentiment based on basic keywords (not AI) — 8 positive, 11 neutral, 1 negative out of the last 20 articles.
Yahoo · 17.9.2026
Benzinga · 27.8.2026
Benzinga · 25.8.2026
MT Newswires · 24.8.2026
Yahoo · 24.8.2026
Business Wire · 24.8.2026
Benzinga · 24.8.2026
Benzinga · 20.8.2026
SeekingAlpha · 18.8.2026
ChartMill · 8.8.2026
Associated Press · 6.8.2026
Business Wire · 6.8.2026
Benzinga · 3.8.2026
Business Wire · 31.7.2026
Business Wire · 27.7.2026
Yahoo · 27.7.2026
Benzinga · 27.7.2026
Business Wire · 10.7.2026
Zacks · 8.7.2026
MT Newswires · 29.6.2026
Precision BioSciences, Inc. (DTIL) currently has a StockIQ AI score of 43/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
DTIL currently scores 43/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
DTIL's technical score is 28/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Current ratio: 13.32; Price is above the 200-day average.
Based on the real signals StockIQ computed: Operating margin: -152.2% (negative); Net margin: -133.4% (negative); ATR: 6.6% of price.
StockIQ has no recorded dividend payment history for DTIL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Brown Melinda | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Buehler Kevin | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Germano Geno J | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Pire Shari Lisa | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Frankel Stanley | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Buehler Kevin | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Pire Shari Lisa | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Germano Geno J | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Frankel Stanley | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Brown Melinda | Grant/Award from Employer | 3.6.2026 | 20,979 | +20,979 | — |
| Kelly John Alexander | Grant/Award from Employer | 1.6.2026 | 193,688 | +193,688 | — |
| Amoroso Michael | Grant/Award from Employer | 1.6.2026 | 573,888 | +573,888 | — |
| SMITH J. JEFFERSON | Grant/Award from Employer | 1.6.2026 | 57,389 | +57,389 | — |
| Scimeca Dario | Grant/Award from Employer | 1.6.2026 | 107,604 | +107,604 | — |
| Amoroso Michael | Grant/Award from Employer | 1.6.2026 | 573,888 | +573,888 | — |
| Kelly John Alexander | Grant/Award from Employer | 1.6.2026 | 193,688 | +193,688 | — |
| Scimeca Dario | Grant/Award from Employer | 1.6.2026 | 107,604 | +107,604 | — |
| SMITH J. JEFFERSON | Grant/Award from Employer | 1.6.2026 | 57,389 | +57,389 | — |
| Frankel Stanley | Exercise of Derivative Securities | 20.5.2026 | 21,000 | +21,000 | — |
| Buehler Kevin | Exercise of Derivative Securities | 20.5.2026 | 21,000 | +21,000 | — |
| Buehler Kevin | Exercise of Derivative Securities | 20.5.2026 | 21,000 | -21,000 | — |
| Pire Shari Lisa | Exercise of Derivative Securities | 20.5.2026 | 21,000 | +21,000 | — |
| Brown Melinda | Exercise of Derivative Securities | 20.5.2026 | 21,000 | +21,000 | — |
| Frankel Stanley | Exercise of Derivative Securities | 20.5.2026 | 21,000 | -21,000 | — |
| Germano Geno J | Exercise of Derivative Securities | 20.5.2026 | 21,000 | +21,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,223,477 shares short as of 2026-09-15 · vs. 2,518,952 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.3% of trading volume this week was short selling, vs. 57.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology